Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P08493

UPID:
MGP_HUMAN

ALTERNATIVE NAMES:
Cell growth-inhibiting gene 36 protein

ALTERNATIVE UPACC:
P08493; A0M8W5; B2R519; J3KMX7; Q2TU41; Q567P9; Q6ICN5

BACKGROUND:
The Matrix Gla protein, with alternative names such as Cell growth-inhibiting gene 36 protein, is integral to bone and cartilage health. It inhibits bone formation, indicating its pivotal role in regulating skeletal development.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Keutel syndrome, characterized by unique symptoms like neural hearing loss and midfacial hypoplasia, the Matrix Gla protein presents a promising target for therapeutic intervention. Exploring its function further could lead to groundbreaking treatments for this autosomal recessive disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.